V15 Gy (HR=0.991, 95%CI, 0.969‐1.013, P=0.034)were the independent risk factors for evident acute intestinal toxicity. Conclusion Dose‐volume parameters of the small bowel can be used as predictors for the occurrence of grade ≥2 acute intestinal toxicity in cervical cancer patients undergoing postoperative adjuvant radiotherapy."/>
宫颈癌术后放疗急性肠道不良反应与剂量‐体积参数相关性
[an error occurred while processing this directive]
Correlation between acute intestinal toxicity and dose-volume parameters in patients with cervical cancer receiving postoperative adjuvant radiotherapy
Xu Bichun, Guo Qi, Qian Jianjun, Cai Shang, Tian Ye
Department of Radiotherapy and Oncology, the Second Affiliated Hospital of Soochow University, Institute of Radiotherapy and Oncology, Soochow University, Suzhou Key Laboratory of Radiotherapy and Oncology, Suzhou 215004, China
Abstract：Objective To identify dose‐volume parameters to predict the incidence of acute intestinal toxicity in cervical cancer patients after postoperative adjuvant radiotherapy. Methods Clinical data of 93 cervical cancer patients who underwent postoperative adjuvant intensity‐modulated radiotherapy (IMRT) were retrospectively evaluated. The dose‐volume parameters comprised the absolute volume of the bowel receiving 5‐45 Gy (5 Gy interval) radiation dose and the total volume of the bowel. The acute radiation-induced intestinal toxicity was evaluated by Radiation Therapy Oncology Group (RTOG) criteria. The association between the irradiated bowel volume and acute intestinal toxicity was analyzed. Results A total of 26 (28%) patients experienced grade ≥2 acute intestinal toxicity. A strong relationship between grade ≥2 acute intestinal toxicity and the irradiated small bowel volume was observed at the total volume of small bowel, small bowel V5 Gy, V10 Gy and V15 Gy (all P<0.05). Small bowel V10 Gy (HR=1.028, 95%CI, 0.993‐1.062, P=0.029) and small bowelV15 Gy (HR=0.991, 95%CI, 0.969‐1.013, P=0.034)were the independent risk factors for evident acute intestinal toxicity. Conclusion Dose‐volume parameters of the small bowel can be used as predictors for the occurrence of grade ≥2 acute intestinal toxicity in cervical cancer patients undergoing postoperative adjuvant radiotherapy.
Xu Bichun,Guo Qi,Qian Jianjun et al. Correlation between acute intestinal toxicity and dose-volume parameters in patients with cervical cancer receiving postoperative adjuvant radiotherapy[J]. Chinese Journal of Radiation Oncology, 2023, 32(3): 235-240.
[1] Wei WQ, Zeng HM, Zheng RS, et al.Cancer registration in China and its role in cancer prevention and control[J]. Lancet Oncol, 2020,21(7):e342-e349. DOI: 10.1016/S1470-2045(20)30073-5. [2] Vordermark D.Radiotherapy of cervical cancer[J]. Oncol Res Treat, 2016,39(9):516-520. DOI: 10.1159/000448902. [3] Wang YN, Kong WM, Lv NN, et al.Incidence of radiation enteritis in cervical cancer patients treated with definitive radiotherapy versus adjuvant radiotherapy[J]. J Cancer Res Ther, 2018,14(Supplement):S120-S124. DOI: 10.4103/0973-1482.163762. [4] Lu LN, Li WJ, Chen LH, et al.Radiation-induced intestinal damage: latest molecular and clinical developments[J]. Future Oncol, 2019,15(35):4105-4118. DOI: 10.2217/fon-2019-0416. [5] Kumagai T, Rahman F, Smith AM.The microbiome and radiation induced-bowel injury: evidence for potential mechanistic role in disease pathogenesis[J]. Nutrients, 2018,10(10):1405. DOI: 10.3390/nu10101405. [6] Small W, Mell LK, Anderson P, et al.Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2008,71(2):428-434. DOI: 10.1016/j.ijrobp.2007.09.042. [7] Klopp AH, Yeung AR, Deshmukh S, et al.Patient-reported toxicity during pelvic intensity-modulated radiation therapy: NRG oncology-RTOG 1203[J]. J Clin Oncol, 2018,36(24):2538-2544. DOI: 10.1200/JCO.2017.77.4273. [8] Lin AJ, Samson P, Zoberi J, et al.Concurrent chemoradiation for cervical cancer: comparison of LDR and HDR brachytherapy[J]. Brachytherapy, 2019,18(3):353-360. DOI: 10.1016/j.brachy.2018.11.008. [9] Laan JJ, van Lonkhuijzen L, van Os RM, et al. Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer[J]. Gynecol Oncol, 2017,147(3):684-689. DOI: 10.1016/j.ygyno.2017.10.013. [10] Reijtenbagh D, Godart J, Mens JM, et al.Patient-reported acute GI symptoms in locally advanced cervical cancer patients correlate with rectal dose[J]. Radiother Oncol, 2020,148:38-43. DOI: 10.1016/j.radonc.2020.03.035. [11] Yang H, Mir R, Díez P, et al.Provision of organ at risk contouring guidance in UK radiotherapy clinical trials[J]. Clin Oncol (R Coll Radiol), 2020,32(2):e60-e66. DOI: 10.1016/j.clon.2019.09.054. [12] Gay HA, Barthold HJ, O'Meara E, et al. Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas[J]. Int J Radiat Oncol Biol Phys, 2012,83(3):e353-362. DOI: 10.1016/j.ijrobp.2012.01.023. [13] Banerjee R, Chakraborty S, Nygren I, et al.Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques[J]. Int J Radiat Oncol Biol Phys, 2013,85(5):1225-1231. DOI: 10.1016/j.ijrobp.2012.09.036. [14] Chopra S, Dora T, Chinnachamy AN, et al.Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study[J]. Int J Radiat Oncol Biol Phys, 2014,88(3):630-635. DOI: 10.1016/j.ijrobp.2013.11.214. [15] Kavanagh BD, Pan CC, Dawson LA, et al.Radiation dose-volume effects in the stomach and small bowel[J]. Int J Radiat Oncol Biol Phys, 2010,76(3 Suppl):S101-107. DOI: 10.1016/j.ijrobp.2009.05.071. [16] Reis T, Khazzaka E, Welzel G, et al.Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea[J]. Radiat Oncol, 2015,10:30. DOI: 10.1186/s13014-015-0336-5. [17] Gogineni E, Bloom B, Diaz Molina F, et al.Radiotherapy dose escalation on pelvic lymph node control in patients with cervical cancer[J]. Int J Gynecol Cancer, 2021,31(4):524-529. DOI: 10.1136/ijgc-2020-001342. [18] Simpson DR, Song WY, Moiseenko V, et al.Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin[J]. Int J Radiat Oncol Biol Phys, 2012,83(1):e81-86. DOI: 10.1016/j.ijrobp.2011.12.012. [19] Lee TF, Huang EY.The different dose-volume effects of normal tissue complication probability using LASSO for acute small-bowel toxicity during radiotherapy in gynecological patients with or without prior abdominal surgery[J]. Biomed Res Int, 2014,2014:143020. DOI: 10.1155/2014/143020. [20] Robertson JM, Lockman D, Yan D, et al.The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer[J]. Int J Radiat Oncol Biol Phys, 2008,70(2):413-418. DOI: 10.1016/j.ijrobp.2007.06.066. [21] Chopra S, Dora T, Chinnachamy AN, et al.Predictors of grade 3 or higher late bowel toxicity in patients undergoing pelvic radiation for cervical cancer: results from a prospective study[J]. Int J Radiat Oncol Biol Phys, 2014,88(3):630-635. DOI: 10.1016/j.ijrobp.2013.11.214. [22] Wagner A, Jhingran A, Gaffney D.Intensity modulated radiotherapy in gynecologic cancers: hope, hype or hyperbole?[J]. Gynecol Oncol, 2013,130(1):229-236. DOI: 10.1016/j.ygyno.2013.04.052.
2023, Vol. 32 
